title: Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats.
abstract: Mesencephalic dopamine neurons form synapses with acetylcholine (ACh)-containing interneurons in the nucleus accumbens (NAcc). Although their involvement in drug reward has not been systematically investigated, these large aspiny interneurons may serve an important integrative function. We previously found that repeated activation of nicotinic cholinergic receptors enhanced cocaine intake in rats but the role of muscarinic receptors in drug reward is less clear. Here we examined the impact of local changes in muscarinic receptor activation within the NAcc on cocaine and food self-administration in rats trained on a progressive ratio (PR) schedule of reinforcement. Animals were given a minimum of 9 continuous days of drug access before testing in order to establish a stable breaking point (BP) for intravenous cocaine infusions (0.75 mg/kg/infusion). Rats in the food group acquired stable responding on the PR schedule within 7 days. On the test day, rats were bilaterally infused in the NAcc with the muscarinic receptor agonist oxotremorine methiodide (OXO: 0.1, 0.3 or 1 nmol/side), OXO plus the M(1) selective antagonist pirenzepine (PIRENZ; 0.3 nmol/side) or aCSF 15 min before cocaine or food access. OXO dose dependently reduced BP values for cocaine reinforcement (-17%, -44% [p<0.05] and -91% [p<0.0001] for 0.1, 0.3 and 1.0 nmol, respectively) and these reductions dissipated by the following session. Pretreatment with PIRENZ blocked the BP-reducing effect of 0.3 nmol OXO. Notably, OXO (0.1, 0.3 and 1.0 nmol/side) injection in the NAcc did not affect BP for food reward. The results suggest that muscarinic ACh receptors in the caudomedial NAcc may play a role in mediating the behavior reinforcing effects of cocaine.
authors.affiliation: Department of Behavioral Neuroscience, L-470, Oregon Health & Science University, School of Medicine, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA. markg@ohsu.edu
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Mark
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Kinney
authors.forename: Michele C
authors.initials: MC
authors.lastname: Grubb
authors.forename: Xiaoman
authors.initials: X
authors.lastname: Zhu
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Finn
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Mader
authors.forename: S Paul
authors.initials: SP
authors.lastname: Berger
authors.forename: Anita J
authors.initials: AJ
authors.lastname: Bechtholt
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D016739:Behavior, Addictive / Q000378:metabolism*; D003042:Cocaine / Q000008:administration & dosage; D019970:Cocaine-Related Disorders / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D008297:Male; D008845:Microinjections; D018721:Muscarinic Agonists / Q000008:administration & dosage*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D010095:Oxotremorine / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism*; D012201:Reward; D012646:Self Administration
chemical_list: D018721:Muscarinic Agonists; D011976:Receptors, Muscarinic; D010095:Oxotremorine; D003042:Cocaine